Serological Response Predicts Normalization of Cerebrospinal Fluid Abnormalities at Six Months after Treatment in HIV-Negative Neurosyphilis Patients

Yao Xiao¹,²,⁴, Man-Li Tong¹,³, Li-Rong Lin¹,³, Li-Li Liu¹,³, Kun Gao², Mei-Jun Chen¹, Hui-Lin Zhang¹, Wei-Hong Zheng¹, Shu-Lian Li⁵, Hui-Ling Lin⁵, Zhi-Feng Lin⁵, Tian-Ci Yang¹,³ & Jian-Jun Niu¹,³,⁴

This study aimed to determine whether a serological response could predict the normalization of cerebrospinal fluid (CSF) abnormalities at 6 months after treatment in human immunodeficiency virus (HIV)-negative neurosyphilis patients. A total of 123 neurosyphilis patients were recruited at baseline, 58 of these patients undergoing treatment, repeated CSF examinations and serological tests for syphilis at 6 months after treatment were included in the follow-up study. Before treatment, the CSF rapid plasma reagin (RPR) titer, CSF *Treponema pallidum* particle agglutination (TPPA) titer, CSF leukocyte count, and CSF protein concentration were correlated with both serum RPR and TPPA titers. At 6 months after treatment, 28 and nine patients achieved serological responses of RPR and TPPA tests, respectively. The sensitivities of the serological response of RPR and TPPA tests for identifying the normalization of CSF abnormalities were 60.0∼83.3% and 17.1~22.2%, respectively; and 75.0∼91.3% of patients showing serological response of RPR test also achieved CSF normalization, suggesting that the serological response could predict CSF normalization to some degree. Particularly, in patients with ≥8-fold decreases in the serum RPR titer, the CSF RPR, CSF leukocyte count, and CSF protein concentration had normalized, and follow-up lumbar puncture could be reduced considering the resolution of neurological symptoms.

Neurosyphilis refers to infection of the central nervous system by *Treponema pallidum*, which may occur at any stage of infection. Conventionally, the diagnosis of neurosyphilis is based on a reactive non-treponemal test (e.g., venereal disease research laboratory [VDRL] test or rapid plasma reagin [RPR] test), pleocytosis and/or elevated protein in cerebrospinal fluid (CSF) collected by lumbar puncture. In recent years, the serological activity of the RPR test was found to be associated with the development of neurosyphilis. In both human immunodeficiency virus (HIV)-infected and HIV-uninfected syphilis patients, those with higher serum RPR titer were reported to have a higher likelihood of neurosyphilis¹. Therefore, the results of serum RPR tests have been recommended as predictors of neurosyphilis to avoid unnecessary lumbar puncture¹,².

In addition to the diagnosis of neurosyphilis, the efficacy of neurosyphilis treatment is mainly assessed by CSF examination. A CSF examination is recommended to be repeated every six months to evaluate changes in CSF parameters and determine the need for retreatment¹. However, performing a lumbar puncture in a clinical setting is logistically difficult, and patients often refuse the procedure. Thus, there is an urgent need to find a surrogate for the normalization of CSF abnormalities after neurosyphilis treatment. Recently, researchers found that a 4-fold...
ponemal tests should not be used to assess disease activity and treatment outcomes. Our preliminary study found the relationship between the serum RPR titer and treatment success remains unclear. Additionally, although treponemal tests showed normalization of clinical and CSF abnormalities, with the exception of the CSF protein concentration, at 13 months after treatment. However, 78% of the study participants had HIV infection and there were allergic to penicillin and were treated with ceftriaxone or doxycycline. These patients were divided into early and late treatment, repeated CSF examinations and serological tests for syphilis at 6 months after treatment were included in the follow-up study. Fifty-three of these patients received the recommended penicillin therapy; the other five patients included 97 males (78.9%) and 26 females (21.1%). Before treatment, all participants had reactive baseline serum RPR (median titer, 1:16; IQR, 1:4–1:64) and serum TPPA tests (median titer, 1:10240; IQR, 1:5120–1:20480). Eighty-six (69.9%) and 114 (92.7%) patients had reactive baseline CSF RPR and CSF TPPA tests (1:1, n (%) 86 (69.9) 45 (77.6)), respectively. The median titers of the CSF RPR and CSF TPPA were 1:2 and 1:1280, respectively. Eighty-three (69.7%) and 67 (55.4%) patients had abnormal baseline CSF leukocyte count and CSF protein concentration, respectively. In this study, the most common stage of neurosyphilis was general paresis (49.6%), followed by meningovascular neurosyphilis (22.8%), syphilitic meningitis (16.3%), tabes dorsalis (7.3%) and asymptomatic neurosyphilis (4.1%).

Results
Clinical characteristics of study participants. The baseline characteristics of 123 neurosyphilis patients are shown in Table 1. The median age of the participants was 52 years (interquartile range [IQR], 46–58 years), and the patients included 97 males (78.9%) and 26 females (21.1%). Before treatment, all participants had reactive baseline serum RPR (median titer, 1:16; IQR, 1:4–1:64) and serum TPPA tests (median titer, 1:10240; IQR, 1:2560–1:20480). Eighty-six (69.9%) and 114 (92.7%) patients had reactive baseline serum RPR and serum TPPA results, respectively. The median titers of the CSF RPR and CSF TPPA were 1:2 and 1:1280, respectively. Eighty-five (69.7%) and 67 (55.4%) patients had abnormal baseline CSF leukocyte count and CSF protein concentration, respectively. In this study, the most common stage of neurosyphilis was general paresis (49.6%), followed by meningovascular neurosyphilis (22.8%), syphilitic meningitis (16.3%), tabes dorsalis (7.3%) and asymptomatic neurosyphilis (4.1%).

Correlations between CSF parameters and reactivity of serum RPR or TPPA before neurosyphilis treatment. The correlations between each CSF parameter and the serum RPR or TPPA titer were evaluated before neurosyphilis treatment (Table 2). Serum RPR titer was correlated with the CSF RPR titer (r = 0.604, P < 0.001), CSF TPPA titer (r = 0.464, P < 0.001), CSF leukocyte count (r = 0.336, P < 0.001) and CSF protein concentration (r = 0.243, P = 0.007). Similarly, the serum TPPA titer was correlated with the CSF RPR titer (r = 0.634, P < 0.001), CSF TPPA titer (r = 0.756, P < 0.001), CSF leukocyte count (r = 0.401, P < 0.001) and CSF protein concentration (r = 0.341, P < 0.001). Neither the serum RPR titer nor the serum TPPA titer was correlated with CSF albumin, CSF glucose, CSF chloride, CSF lactate or CSF lactate dehydrogenase.

Associations between normalization of CSF abnormalities and serological response of RPR or TPPA test at 6 months after neurosyphilis treatment. Eighty-eight neurosyphilis patients undergoing treatment, repeated CSF examinations and serological tests for syphilis at 6 months after treatment were included in the follow-up study. Fifty-three of these patients received the recommended penicillin therapy; the other five were allergic to penicillin and were treated with ceftriaxone or doxycycline. These patients were divided into early

| Characteristics | Neurosyphilis at baseline (n = 123) | Neurosyphilis enrolled in follow-up (n = 58) |
|-----------------|----------------------------------|------------------------------------------|
| Sex ratio (male: female) | 97:26                            | 47:11                                    |
| Age, median years (IQR) | 52 (46–58)                        | 50 (44–57)                               |
| Baseline serum RPR titer, median (IQR) | 1:16 (1:4–1:64)                  | 1:32 (1:16–1:64)                        |
| ≥1:1, n (%) | 123 (100)                        | 58 (100)                                |
| Baseline serum TPPA titer, median (IQR) | 1:10240 (1:2560–1:20480)         | 1:10240 (1:5120–1:20480)                |
| ≥1:80, n (%) | 123 (100)                        | 58 (100)                                |
| Baseline CSF RPR titer, median (IQR) | 1:2 (negative-1:4)               | 1:2 (1:1–1:4)                           |
| ≥1:1, n (%) | 86 (69.9)                        | 45 (77.6)                               |
| Baseline CSF TPPA titer, median (IQR) | 1:1280 (1:320–1:10240)           | 1:2560 (1:320–1:10240)                 |
| ≥1:80, n (%) | 114 (92.7)                       | 54 (93.1)                               |
| Baseline CSF leukocyte count, median (IQR) | 21 (6–54)                       | 18 (10–56)                              |
| >10 cells/µL, n (%) | 85 (69.7)                        | 43 (74.1)                               |
| Baseline CSF protein concentration, median (IQR) | 572.1 (392.3–882.9)             | 632.0 (458.0–867.0)                    |
| >500 mg/L, n (%) | 67 (55.4)                        | 34 (58.6)                               |
| Clinical stages, n (%) |                                   |                                         |
| Asymptomatic neurosyphilis | 5 (4.1)                          | 4 (6.9)                                 |
| Syphilitic meningitis | 20 (16.3)                        | 8 (13.8)                                |
| Meningovascular neurosyphilis | 28 (22.8)                       | 13 (22.4)                               |
| General paresis | 61 (49.6)                        | 29 (50.0)                               |
| Tabes dorsalis | 9 (7.3)                          | 4 (6.9)                                 |

Table 1. Clinical characteristics of the study participants. Abbreviations: IQR, interquartile range; RPR, rapid plasma reagin; TPPA, T. pallidum particle agglutination; CSF, cerebrospinal fluid.
Table 2. Correlations between CSF parameters and reactivity of serum RPR or TPPA before neurosyphilis treatment (n = 123). Abbreviations: RPR, rapid plasma reagin; TPPA, T. pallidum particle agglutination; CSF, cerebrospinal fluid.

| CSF parameters                  | Serum RPR titer | Serum TPPA titer |
|---------------------------------|-----------------|-----------------|
|                                 | $r_c$           | $P$             | $r_c$           | $P$             |
| CSF RPR titer                   | 0.604           | <0.001          | 0.634           | <0.001          |
| CSF TPPA titer                  | 0.464           | <0.001          | 0.756           | <0.001          |
| CSF leukocyte count             | 0.336           | <0.001          | 0.401           | <0.001          |
| CSF protein concentration       | 0.243           | 0.007           | 0.341           | <0.001          |
| CSF albumin                     | 0.093           | 0.429           | 0.219           | 0.063           |
| CSF glucose                     | −0.168          | 0.065           | −0.038          | 0.678           |
| CSF chloride                    | 0.125           | 0.173           | −0.126          | 0.172           |
| CSF lactate                     | 0.162           | 0.169           | 0.190           | 0.108           |
| CSF lactate dehydrogenase       | −0.124          | 0.294           | −0.088          | 0.457           |

Table 3. Sensitivities and positive predictive values of serological responses of RPR and TPPA tests for predicting normalization of CSF abnormalities at 6 months after neurosyphilis treatment. *Sensitivity was calculated as the number of patients in whom both CSF abnormalities normalized and serum RPR titer responded divided by the sum of these patients and the number of patients in whom CSF abnormalities did not normalize but serum RPR titer did not respond. †Positive predictive value (PPV) was calculated as the number of patients in whom both CSF abnormalities normalized and serum RPR titer responded divided by the sum of these patients and the number of patients in whom CSF abnormalities did not normalize but serum RPR titer did respond. PPV is the percentage of patients in whom response of serum RPR titer predicts normalization of CSF abnormalities.

The associations between the normalization of CSF abnormalities and serological response of RPR or TPPA test were analyzed for the late syphilis subgroup. Among 26 patients with CSF RPR responses, 18 achieved a serological response of RPR test, and one achieved a serological response of TPPA test. No patients had reactive baseline CSF RPR. Two patients had an abnormal baseline CSF leukocyte count, and one of them exhibited normalization at 6 months after treatment. One patient had an abnormal baseline CSF protein concentration and exhibited normalization. The early syphilis subgroup was not included in further statistical analyses due to the small sample size.

In the late syphilis subgroup, which consisted of 18 late syphilis patients and 37 patients with syphilis of unknown duration, 28 (50.9%) and eight (14.5%) patients achieved serological responses of RPR and TPPA tests, respectively. A ≥4-fold increase in the serum RPR or TPPA titer was not observed during the study period. Of 45 patients with reactive baseline CSF RPR, 26 (57.8%) achieved a response of CSF RPR test. Of 41 patients with an abnormal baseline CSF leukocyte count, 35 (85.4%) exhibited a normalized CSF leukocyte count. Of 33 patients with an abnormal baseline CSF protein concentration, 18 (54.5%) exhibited a normalized CSF protein concentration.

The associations between the normalization of CSF abnormalities and serological response of RPR or TPPA test were analyzed for the late syphilis subgroup. Among 26 patients with CSF RPR responses, 18 achieved a serological response of RPR test, and five achieved a serological response of TPPA test. The sensitivities of the serological responses of RPR and TPPA tests for identifying a response of CSF RPR were 69.2% and 19.2%, respectively ($P = 0.001$). Similarly, the sensitivities of the serological response of the RPR test for identifying normalization of the CSF RPR test were 60.0% and 83.3%, respectively. These values were higher than the respective sensitivities of the serological response of TPPA test (60.0% vs. 17.1%, $P < 0.001$; 83.3% vs. 22.2%, $P = 0.001$; Table 3). Among 28 patients who achieved a serological response of RPR test, 22 patients had reactive baseline CSF RPR, and 18 (positive predictive value [PPV], 81.8%) achieved CSF RPR responses. The median decrease in the CSF RPR titer was 4-fold (IQR, 2-fold to 4-fold). Twenty-three patients had an abnormal baseline CSF leukocyte count, and 21 (PPV, 91.3%) exhibited a normalized CSF leukocyte count. The median decrease in the CSF leukocyte count was 28 cells/μL (IQR, 8–78 cells/μL). Twenty patients had an abnormal baseline CSF protein concentration, and 15 (PPV, 75.0%) exhibited a normalized CSF protein concentration. The median decrease in the CSF protein concentration was 353 mg/L (IQR, 299–463 mg/L). Among the eight patients who achieved a serological response of TPPA test, five of six (PPV, 83.3%) had CSF RPR responses, six of seven (PPV, 85.7%) had a normalized CSF leukocyte count, and four of five (PPV, 80.0%) had a normalized CSF protein concentration (Table 3).
patients with reactive baseline CSF RPR were included. b41 patients with an abnormal baseline CSF leukocyte

tion. The quantitation of treponemal antibody is possible but has not been demonstrated to be worthwhile10.

due to persistent positive results for life. As a quantitative treponemal test, the TPPA test is based on agglutina-

eurosyphilis patients before treatment. In contrast, treponemal tests are considered irrelevant to disease activity

RPR titer and several CSF parameters (including CSF RPR titer, CSF TPPA titer, and CSF leukocyte count) in

6 months after neurosyphilis treatment. Abbreviations: RPR, rapid plasma reagin; CSF, cerebrospinal fluid. a45

Table 4. Varying decreases in serum RPR and TPPA titers in predicting normalization of CSF abnormalities at

6 months after neurosyphilis treatment. Abbreviations: RPR, rapid plasma reagin; CSF, cerebrospinal fluid. 445

Varying decreases in serum RPR and TPPA titers in predicting normalization of CSF abnormalities at 6 months after neurosyphilis treatment. We further analyzed the CSF profiles of patients with varying decreases in serum RPR and TPPA titers for the late syphilis subgroup. Fourteen patients exhibited no decrease in the serum RPR titer. Among these patients, 12 had reactive baseline CSF RPR, and 25.0% (3/12) achieved CSF RPR responses. Furthermore, 77.8% had a normalized CSF leukocyte count, and 25.0% had a normalized CSF protein concentration. Fourteen patients had a 2-fold decrease, 19 patients had a 4-fold decrease, four patients had an 8-fold decrease, and four patients had a 16-fold decrease in the serum RPR titer. As the serum RPR titer decreased, the normalization of CSF abnormalities increased. In patients whose serum RPR titer decreased ≥8-fold, the CSF RPR, CSF leukocyte count, and CSF protein concentration had normalized (Table 4). Unlike the serum RPR titer, the serum TPPA titer did not decrease in 60.0% (33/55) of participants. Nonetheless, among patients who presented a 4-fold decrease in serum TPPA titer, 83.3%, 85.7% and 80.0% exhibited a CSF RPR response, normalization of the CSF leukocyte count and normalization of the CSF protein concentration, respectively.

Discussion
The success of neurosyphilis treatment is commonly determined by the resolution or stabilization of clinical abnormalities and the normalization of CSF abnormalities. However, clinical abnormalities are more likely to resolve in early neurosyphilis. In contrast, patients with dementia or tabes are unlikely to show reversal9. Therefore, CSF assessment is an objective method for monitoring the effectiveness of therapy. Typically, neurosyphilis patients are recommended to undergo repeated lumbar punctures every 6 months after treatment until the CSF profiles become normal1. In HIV-infected patients, Marra et al.4 observed that the odds of normalization of the CSF VDRL titer, CSF leukocyte count and CSF protein concentration after treatment were 57.7, 41.4 and 28-fold higher, respectively, when the serum RPR titer had normalized than when it had not. These researchers noted that a reduction in the serum RPR titer could serve as a surrogate for the normalization of CSF and clinical abnormalities after neurosyphilis treatment. In the present study, we examined this possibility in an HIV-negative population and analyzed whether variations in serum TPPA can predict the normalization of CSF.

A high serum RPR titer has been reported to be associated with an increased likelihood of neurosyphilis1. An increase in the RPR titer can reflect recent infection, re-infection or relapse. Therefore, the titer level is considered to be generally correlated with disease activity9. In the present study, we observed correlations between the serum RPR titer and several CSF parameters (including CSF RPR titer, CSF TPPA titer, and CSF leukocyte count) in neurosyphilis patients before treatment. In contrast, treponemal tests are considered irrelevant to disease activity due to persistent positive results for life. As a quantitative treponemal test, the TPPA test is based on agglutination. The quantitation of treponemal antibody is possible but has not been demonstrated to be worthwhile10. However, we found that the serum TPPA titer was also correlated with those CSF profiles before treatment. Our results suggest that serological activity of both the RPR and TPPA tests could reflect CSF abnormalities before neurosyphilis treatment.

Furthermore, we determined whether seroreactivity continues to reflect the CSF profiles after neurosyphilis treatment. Among the 55 patients involved in this analysis, 28 achieved a serological response of RPR test, whereas only eight achieved a serological response of TPPA test at 6 months after treatment. A serological

| Decrease in serum RPR titer | Response of CSF RPR test n/N (%) | Normalization of CSF leukocyte count n/N (%) | Normalization of CSF protein concentration n/N (%) |
|-----------------------------|---------------------------------|-------------------------------------------|--------------------------------------------------|
| Null (14 patients)          | 3/12 (25.0)                     | 7/9 (77.8)                                | 2/8 (25.0)                                       |
| 2-fold (14 patients)        | 5/11 (45.5)                     | 7/9 (77.8)                                | 1/5 (20.0)                                       |
| 4-fold (19 patients)        | 11/15 (73.3)                    | 15/17 (88.2)                              | 10/15 (66.7)                                     |
| 8-fold (4 patients)         | 4/4 (100.0)                     | 4/4 (100.0)                               | 2/2 (100.0)                                      |
| 16-fold (4 patients)        | 3/3 (100.0)                     | 2/2 (100.0)                               | 3/3 (100.0)                                      |

| Decrease in serum TPPA titer | Response of CSF RPR test n/N (%) | Normalization of CSF leukocyte count n/N (%) | Normalization of CSF protein concentration n/N (%) |
|-----------------------------|---------------------------------|-------------------------------------------|--------------------------------------------------|
| Null (33 patients)          | 12/28 (42.9)                   | 20/24 (83.3)                               | 10/19 (52.6)                                     |
| 2-fold (14 patients)        | 9/11 (81.8)                    | 9/10 (90.0)                               | 4/9 (44.4)                                       |
| 4-fold (6 patients)         | 5/6 (83.3)                     | 6/7 (85.7)                               | 4/5 (80.0)                                       |
The CSF examination and serological tests for syphilis were performed using RPR (InTec, Xiamen, China) and TPPA (Fujirebio, Tokyo, Japan) tests according to the manufacturers’ instructions and as previously reported
cited in the text after the author’s name as 4–10. In this study, at 6 months after neurosyphilis treatment, a serological response of RPR or TPPA test was defined as a ≥4-fold (2 dilutions) decrease in titer (e.g., from 1:16 to 1:4 or from 1:5120 to 1:1280) or reversion of the test to nonreactive. A serological nonresponse was defined as a <4-fold decrease or any increase in titer. A response of CSF RPR test was defined as a ≥4-fold decrease in titer or reversion of the test to nonreactive. Normalization of the CSF leukocyte count was defined as a decrease from >10 cells/μL to ≤10 cells/μL. Normalization of the CSF protein concentration was defined as a decrease from >500 mg/L to ≤500 mg/L.

Laboratory tests. The CSF examination and serological tests for syphilis were performed using RPR (InTec, Xiamen, China) and TPPA (Fujirebio, Tokyo, Japan) tests according to the manufacturers’ instructions and as previously reported
cited in the text after the author’s name as 4–10. In this study, at 6 months after neurosyphilis treatment, a serological response of RPR or TPPA test was defined as a ≥4-fold (2 dilutions) decrease in titer (e.g., from 1:16 to 1:4 or from 1:5120 to 1:1280) or reversion of the test to nonreactive. A serological nonresponse was defined as a <4-fold decrease or any increase in titer. A response of CSF RPR test was defined as a ≥4-fold decrease in titer or reversion of the test to nonreactive. Normalization of the CSF leukocyte count was defined as a decrease from >10 cells/μL to ≤10 cells/μL. Normalization of the CSF protein concentration was defined as a decrease from >500 mg/L to ≤500 mg/L.
cardiolipin antigens. Approximately 50 μL of serum was dispensed over the card, followed by a drop of the antigen suspension. The card was placed on a rotating plate at 100 rpm for 8 min to mix the antigen suspension and serum. Readings were obtained immediately with the naked eye through comparisons with negative and positive controls. The serum samples that reacted to RPR were quantified using 2-fold serial dilutions. The TPPA assay is based on the agglutination of colored gelatin particles that have been sensitized (coated) with T. pallidum (Nichols strain) antigen. The initial dilution of the serum samples used in the TPPA reactions was 1:80. Two standard serum samples (including 400 mIU/mL and 80 mIU/mL) (Beijing Controls & Standards Biotechnology Co., Ltd., China) were used as controls for the RPR and TPPA reactions, respectively. Serum samples that produced conflicting or inconclusive results for a particular technique were tested again; the new result was considered the true result.

CSF samples (approximately 2 mL) were collected within a time frame of 2 h. Blood (5 mL) was collected in plain sterile tubes from patients who had fasted for at least 8 h. The blood was then centrifuged within 10 min and analyzed within 4 h. The protein, albumin, lactate, lactate dehydrogenase, chloride, and glucose levels in the CSF samples were measured using a Roche-Hitachi Modular P800 Analyzer (Roche Diagnostics, F. Hoffmann-La Roche, Ltd., Basel, Switzerland). The CSF leukocyte count was measured using an Automatic Blood Cell XE5000 Analyzer (Sysmex International Reagents, Co., Ltd, Japan).

Statistical analysis. Spearman’s rank correlation was used to analyze the correlations between each of the CSF parameters and the reactivity of both serum RPR and serum TPPA. Serum RPR and serum TPPA, which are quantitative measures with serial 2-fold dilutions, were log2 transformed for the correlation analysis. McNemar’s test was used to compare the sensitivities of the serological responses of RPR and TPPA tests for identifying the normalization of CSF abnormalities. The statistical analyses were performed using SPSS 19.0 for Windows (SPSS Inc., Chicago, IL, USA). A two-sided P-value of <0.05 was considered statistically significant.

References
1. Marra, C. M. et al. Cerebrospinal fluid abnormalities in patients with syphilis: Association with clinical and laboratory features. J Infect Dis 189, 369–376 (2004).
2. Shi, M. et al. Risk profiles of neurosyphilis in HIV-negative patients with primary, secondary and latent syphilis: Implications for clinical intervention. J Eur Acad Dermatol Venereol 30, 659–666 (2015).
3. Workowski, K. A. & Bolan, G. A. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 64, 1–137 (2015).
4. Marra, C. M., Maxwell, C. L., Tantalo, L. C., Sahi, S. K. & Lukehart, S. A. Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis. Clin Infect Dis 47, 893–899 (2008).
5. Knaut, D. F., Graf, N., Lautenschlager, S., Weber, R. & Bossard, P. P. Serological response to treatment of syphilis according to disease stage and HIV status. Clin Infect Dis 55, 1615–1622 (2012).
6. Janier, M. et al. European guideline on the management of syphilis. J Eur Acad Dermatol Venereol 28, 1581–1593 (2014).
7. Xiao, Y. et al. Novel predictors of neurosyphilis among HIV-negative syphilis patients with neurological symptoms: An observational study. BMC Infect Dis 17, 310 (2017).
8. Marra, C. M. Neurosyphilis. Continuum (Minneap Minn) 21, 1714–1728 (2015).
9. Lin, L. R. et al. Further evaluation of the characteristics of Treponema pallidum-specific IgM antibody in syphilis serofast reaction patients. Diagn Microbiol Infect Dis 71, 201–207 (2011).
10. Larsen, S. A., Steiner, B. M. & Rudolph, A. H. Laboratory diagnosis and interpretation of tests for syphilis. Clin Microbiol Rev 8, 1–21 (1995).
11. Marra, C. M. et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: Does HIV status matter? Clin Infect Dis 38, 1001–1006 (2004).
12. Centers for Disease Control and Prevention. STD surveillance case definitions. Centers for Disease Control and Prevention. http://www.cdc.gov/std/stats/CaseDefinitions-2014.pdf (2014).
13. French, P. et al. IUSTI: 2008 European Guidelines on the Management of Syphilis. Int J STD AIDS 20, 300–309 (2009).
14. Liu, L. L. et al. Assessing cerebrospinal fluid abnormalities in neurosyphilis patients without human immunodeficiency virus infection. *Int Immunopharmacol* **17**, 1120–1124 (2013).

15. Xiao, Y. et al. Factors associated with syphilis infection: A comprehensive analysis based on a case-control study. *Epidemiol Infect* **144**, 1165–1174 (2016).

16. Liu, F. et al. Characterization of the classical biological false-positive reaction in the serological test for syphilis in the modern era. *Int Immunopharmacol* **20**, 331–336 (2014).

**Acknowledgements**

This study was supported by the National Natural Science Foundation [Grant numbers 81672094, 81471967, 81471231, 81401749, 81301501, 81201360, 81271335, 81101324, 81171625], the Key Projects in Fujian Province Science and Technology Program [Grant numbers 2014D021], the Projects of Xiamen Science and Technology Program [Grant numbers 3502Z20144022, 3502Z20154015, WSK2010–01], the Key Project of Cultivating Young Talent in Fujian Province's Health System [Grant numbers 2014-ZQN-ZD-34], the Young Researcher Project of Fujian Provincial Health and Family Planning Commission [Grant number 2017-2-105], the National Science Foundation for Distinguished Young Scholars of Fujian [Grant number 2014D001], the medical innovation Project of Fujian Health Development Planning Commission [Grant number 2014-CXB-40], the major special projects of serious illness in Xiamen [Grant number 3502Z20159016], and the Natural Science Foundation of Fujian Province [Grant number 2016(0)1628], The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Author Contributions**

Y.X., M.-L.T., and L.-R.L. wrote the main manuscript text, L.-L.L., K.G., and M.-J.C. contributed to statistical analysis and revision of manuscript. H.-L.Z., W.-H.Z., S.-L.L., H.-L.L., and Z.-F.L. supervised the sample collection, T.-C.Y. and J.-J.N. designed the study.

**Additional Information**

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017